Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry

Afaf Abdel-Aziz Abdel-Ghafar,
Manal Ahmed Shams El Din El Telbany,
Hanan Mohamed Mahmoud,
Yasmin Nabil El-Sakhawy

Clinical and Chemical Pathology, Faculty
of Medicine, Ain Shams University, Cairo,
Egypt

Abstract

Morphological differentiation between benign and malignant lymphoproliferative disorders (LPDs) can be challenging. Immunophenotyping (IPT) by either technique, flow cytometry or immunohistochemistry (IHC), is an important step in solving such difficulty. Thirty-five newly diagnosed patients with chronic B-cell neoplasms (11 chronic lymphocytic leukemia, 22 non Hodgkin lymphoma and 2 hairy cell leukemia) were included in this study with age range from 20 to 70 years. Monoclonal antibodies surface expression using lymphoproliferative disorders panel (CD45, CD19, CD5, CD10, CD11c, CD20, CD22, CD23, CD38, CD79b, FMC7, CD103, CD25, kappa and lambda light chains) by flow cytometry was done on bone marrow samples. CD20, CD5, CD23, Bcl-2, Bcl-6, kappa and lambda light chain immunostaining were performed on fixed bone marrow trephine biopsy specimen. The sensitivity of IHC was 81.8% in chronic lymphocytic leukemia (CLL) and 100% in non Hodgkin lymphoma (NHL) as regards CD20, 100% in both groups as regards CD5, 46% in CLL and 66.7% in NHL as regards CD23, 33.3% in CLL and 50% in NHL as regards kappa chain, 20% in CLL and 33.3% in NHL as regards lambda chain. We found that IHC and flow cytometry are equally effective in diagnosing CLL; however, IHC might be slightly more sensitive than flow cytometry in detecting bone marrow infiltration in NHL and hairy cell leukemia (HCL).

Introduction

Distinguishing benign and malignant lymphoproliferative disorders (LPDs) by purely morphologic criteria can be difficult. Immunophenotypic analysis is a useful adjunct to the morphologic evaluation of LPDs and is of considerable assistance in resolving difficult diagnostic dilemmas. The advent of immunophenotyping (IPT) of samples from patients with LPDs has added much for

proper diagnosis and classification and for better understanding of the pathogenetic mechanisms underlying the development of these disorders.¹

There are several ways for testing cell markers, such as flow cytometry in which suspensions of viable or fixed cells are tested, and immunohistochemistry which studies cells in frozen or paraffin-embedded sections from bone marrow biopsy specimens or other hemopoietic tissues.²

In immunohistochemistry (IHC), morphology and antigen label can be visualized simultaneously by light microscopy which is not the case in flow cytometry, enabling accurate identification of the cells or region of interest.³ It is considered more suitable in the detection of partial or focal involvement by neoplastic cells and it is also more beneficial in nuclear antigen assessment.⁴ Another privilege of IHC is the long-term preservation of the biological specimen after processing and the ability to re-examine it at any time.⁵

The aim of this study was to identify the diagnostic role of IHC in chronic B-cell neoplasms using a selected panel of monoclonal antibodies and to compare this role to that of flow cytometry.

Materials and Methods

Subjects

This study comprised 35 newly diagnosed chronic B-cell neoplasms adult patients attending the hematological unit of clinical pathology department, Ain Shams University, Cairo, Egypt. Patients were recruited to the study on the basis of clinical, laboratory, bone marrow aspirate and trephine biopsy findings and immunophenotypic criteria of chronic B-cell neoplasms. Sometimes lymph nodes biopsy results were provided to confirm the diagnosis.

They were 22 males and 13 females with a male to female ratio 1.7:1.0. Their ages ranged from 20 to 70 years old with mean of 51 ± 15.2 years. The 35 patients were divided into 3 groups: chronic lymphocytic leukemia (CLL) group (11 patients), non Hodgkin lymphoma (NHL) group (22 patients) and hairy cell leukemia (HCL) group (2 patients). The 22 NHL cases comprised 8 mantle cell lymphomas, 6 follicular lymphomas, 5 diffuse large B-cell lymphomas and 3 Burkitt's lymphomas.

Patients were subjected to clinical sheet details (with special concern to organomegaly, lymphadenopathy, fever and weight loss), complete blood count with examination of peripheral blood smears stained with Leishman stain, bone marrow aspiration, bone marrow trephine biopsy, flow cytometric immunophenotyping for cases in leukemic phase using lymphoproliferative disorders panel (CD45, CD19, CD5, CD10, CD11c, CD20, CD22, CD23, CD38, CD79b, FMC7, CD103, CD25, kappa and lambda light chains). CD20, CD5, CD23, Bcl-2, Bcl-6, kappa and lambda light

Correspondence: Yasmin Nabil, Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, El Abbassia Square, Cairo, Egypt.

Tel. +20.224.845.802 - Fax: +20.224.845.802.

E-mail: yasminnabil@hotmail.com

Key words: chronic B- LPD, immunohistochemistry, immunophenotyping.

Received for publication: 26 August 2011.

Revision received: 4 November 2011.

Accepted for publication: 22 December 2011.

This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).

©Copyright A.A.A. Abdel-Ghafar et al., 2012

Licensee PAGEPress, Italy

Hematology Reports 2012; 4:e3

doi:10.4081/hr.2012.e3

chain immunostaining was performed on fixed bone marrow trephine biopsy specimen.

Specimens

Two milliliters peripheral blood samples were collected in a sterile ethylene-diamine-tetraacetic acid (EDTA) containing vacutainers for CBC. Bone marrow (BM) aspiration was withdrawn; the first few drops were spread on glass slides for morphological examination and 1 mL into sterile EDTA containing vacutainers for IPT. For IPT by flow cytometry samples were processed within 24 hours. BM trephine core biopsy was obtained and transferred immediately in a sterile plastic cup containing aldehyde solution as a fixative.

Methods

Flow cytometry

Samples were processed using whole blood lysis method and analysis was done using 4 colour flow cytometric analyzer (Coulter EPICS-XL flow cytometer with system II software) USA. FCM quality control including alignment, calibration, and color compensation was performed before sample acquisition according to manufacturer's instructional manual. Samples were diluted 1:1 with phosphate buffered-saline (PBS), pH 7.4 (Sigma Chemicals, St Louis). The final cell count suspension was adjusted between 5 and $10 \times 10^6/L$: 50 uL of each sample was pipetted in two tubes (one test tube and one control tube); 5 uL of MoAbs fluorescein isothiocyanate (FITC), or phycoerythrin (PE) labeled (Provided by Coulter electronics, USA) were added to the test tube while 5 uL of isotype matched conjugated Igs to determine the non specific binding were added to the control tube. Tubes were gently vortexed and incubated 15 min at room temperature in the dark. One mL lysing solution was added to each

tube for 2-5 min and mixed well. At the end 1 mL PBS was added. Sequential gates were applied; initially, the lymphoid cells window was defined by forward scatter/side scatter and CD45/side scatter patterns. At least 20% of cells should express the marker to be considered positive for immunophenotyping panel. For all monoclonal expression both percent positivity and staining intensity of cells were determined.

Immunohistochemistry

Fixation was performed for 24 hours then decalcification of the core was done using disodium EDTA for 48 hours. This was followed by passing the core in serial concentrations of ethyl alcohol (50%, 70%, 85%, 90%, and 100%) ending with xylene then wax followed by paraffin embedding. Serial 3- μ m sections were cut from the paraffin block, mounted on positively charged slides and dried overnight in a 60°C oven. Deparaffinization in xylene for 24 hours followed by hydration in descending grades of alcohol; 100%, 90%, 85% and 70% was done. Antigen unmasking was done by heat induced epitope retrieval (HIER) method using antigen retrieval solution (Dako, Denmark) with PH 6.0, for a period of 20 min in a microwave at 800 Watt.

Endogenous peroxidase activity was blocked by incubation of the tissue section with 3% hydrogen peroxide in water for 30 min followed by incubation with the primary monoclonal antibody (Dako, Denmark) (Table 1). The streptavidin-biotin method with the horseradish peroxidase enzyme was used as a detection kit (LSAB2, Dako, Denmark). The sections were then counterstained in Meyer hematoxylin, cover-slipped by DPX mount media and examined under light microscope. The positivity of the immunostaining was detected by percentage of positive cells, intensity and pattern of staining (Table 1). According to percentage of positive cells: four grades were identified; 0: no reaction, 1+: <5%, 2+: 5-9%, 3+: 10-20% and 4+: $\geq$ 20%. Monoclonality was confirmed by either κ/λ ratios of more than 3 (κ clone) or less than 0.4 (λ clone).⁴

Statistical analysis

Data was analyzed statistically using statistical package for social science (SPSS version 15.0.1). The following tests were done: descriptive statistics including quantitative data (mean $\pm$ standard deviation) for parametric results and in the form of median and range in non parametric ones) and qualitative data (number and percentage), analytical statistics including χ^2 , Fisher's exact test, Wilcoxon Rank-sum test (Z-value) and regarding quantitative parametric data using Student test (t-value).

Results

In the CLL group (11 patients), the BM aspirate lymphocytes percentage ranged from 40% to 98% with a mean of 82.9 $\pm$ 16.0. In the NHL cases (22 patients), the BM aspirate lymphocytes ranged from 6% to 92% with a mean of 24.8 $\pm$ 22.9. Seven (31.8%) cases of the NHL group had BM lymphocyte count $\geq$ 30% (BM infiltration), while 13 (59.1%) cases had lymphocyte count <30%. Dry tap was observed in 2 cases. Bone marrow trephine biopsy showed lymphocytic infiltration in all patients. In the CLL group, ten cases showed diffuse pattern of infiltration with packed marrow and one case showed interstitial

pattern of infiltration together with scattered nodules of small lymphocytes. In the NHL group, the predominant pattern of infiltration was the mixed pattern (8/22, 36.4%), followed by the focal pattern (7/22, 31.8%), the interstitial pattern (4/22, 18.2%) and the diffuse pattern (3/22, 13.6%). In the two HCL cases, both showed mixed (patchy and interstitial) pattern of infiltration.

Flow cytometry

All CLL cases had a score of 4-5 while in the NHL group the score was 0-2 according to Matutes and Moreau;^{6,7} immunophenotyping on BM aspirate was performed in infiltrated cases which were 7 out of 22 cases (Figures 1, 2).

Table 1. Monoclonal antibodies.

Primary antibody	Clone	Dilution	Time of incubation	Grade	Pattern of staining
CD20	L26	Ready to use	One hour	4+	Membranous/Cytoplasmic
CD5	CD5/54/F6	Ready to use	One hour	3+	Membranous/Cytoplasmic
CD23	MHM6	1:5	One hour	3+	Membranous/Cytoplasmic
Bcl-2	124	Ready to use	One hour	4+	Membranous/Cytoplasmic
Bcl-6	PG-B6p	1:10	Overnight at 4°C	3+	Nuclear
Kappa	R10-21-F3	Ready to use	Two hours	2+	Perinuclear/Granular cytoplasmic
Lambda	N10/2	Ready to use	Two hours	2+	Perinuclear/Granular cytoplasmic

All monoclonals were purchased from life trade company Egypt imported from Dako Denmark.

Figure 1. Flow cytometric analysis of a case of chronic lymphocytic leukemia (score=5).

In CLL group, all cases (100%) revealed CD19, CD20 (72.7% of them with dim intensity), CD5 and CD23, 87.5% expressed CD22, 67.5% were negative for CD79b, 77.5% were negative for FMC7 and 35% expressed CD38. Smlg light chain restriction showed κ restriction in 54.5% and λ in 45.5% of cases. In NHL group, the lymphocytes expressed pan B cell markers, CD19 (100%), CD20 (100% with bright intensity), CD22 (85.7%) and CD79b (85.7%, bright expression); CD5 and CD23 were expressed in 3/7 cases (42.9%); CD10 was expressed in one case.

Immunohistochemistry

Figures 3-8 show examples of immunohistochemistry results. CD20 showed positivity in 81.8% (9/11) of the CLL group showing 45.4% of cases with strong intensity, 18.2% with moderate intensity and 18.2% with weak intensity. In NHL group, positivity was detected in 95.5% (21/22) of cases showing 45.5% of cases with strong intensity, 36.4% with moderate intensity and 13.6% showed weak intensity in NHL group. Concerning CD5, it was expressed in 100% (11/11) with 45.5% showed strong intensity, 36.3% with moderate intensity and 18.2% with weak intensity in CLL group, 50% (11/22) of cases showing 22.8% with strong intensity, 18.2% with moderate intensity and 9% with weak intensity in the NHL.

Figure 2. Flow cytometric analysis of a case of non Hodgkin lymphoma (score=2).

Figure 3. A case of chronic lymphocytic leukemia showing positive CD20.

Figure 4. A case of chronic lymphocytic leukemia showing positive CD5.

Figure 5. A case of chronic lymphocytic leukemia showing positive CD23.

Figure 6. Light chain restriction: kappa restriction in a case of chronic lymphocytic leukemia.

Figure 7. A case of chronic lymphocytic leukemia showing positive Bcl2.

Figure 8. A case of Diffuse large B-cell lymphoma showing positive Bcl6.

As regards CD23, it was expressed in 45.5% (5/11) showing 9% with strong intensity, 9% with moderate intensity and 27.5% with weak intensity and in 13.6% (3/22) of cases of the CLL group. All cases of NHL showed weak intensity. Three cases (27.7%) of the CLL group, all of them had weak intensity and 12/22 (54.5%) of NHL group showed light chain restriction with all cases had moderate intensity. As for Bcl-2 protein, it was positive in 54.5% (6/11) & in 36.4% (8/22) of cases of the CLL and NHL groups. Bcl-6 was positive in 13.6% (3/22) of NHL cases and it was negative in CLL group.

Comparing immunohistochemistry to flow cytometry results

The percent positivity of markers and staining intensity done using IHC were compared to the percent positivity and to the mean fluorescence intensity of these markers using flow cytometry. In the CLL group, no statistical significance was found regarding all markers except for CD20 mean fluorescence intensity ($P=0.002$), however, within the NHL group, there was a significant relation between the percent positivity of both flow cytometry and IHC regarding CD20 ($P=0.01$), CD5 ($P=0.02$), CD23 ($P=0.049$), κ ($P=0.025$) and highly significant one for λ ($P=0.006$) (Table 2). The significant association was restricted to CD20 and CD5 when comparing their IHC positivity to MFI by flow cytometry ($P=0.002$ and 0.04 respectively) (Table 3). On the other hand, comparing the IHC staining intensity (graded as strong, moderate and weak) to the flow cytometry results showed a high statistical significance as regards CD5 either its percent positivity or its MFI ($P=0.008$, 0.039 respectively). Another significance was found regarding CD20 MFI ($P=0.049$). No statistical significance was found as regards other markers.

Sensitivity of immunohistochemistry markers

The sensitivity of IHC markers was calculated in both CLL and NHL groups which revealed a sensitivity of 81.8% for the CLL group and 100% in NHL group as regards CD20, 100% in both groups as regards CD5, 46% in CLL group and 66.7% in NHL group as regards CD23, 33.3% in CLL group and 50% in NHL group as regards kappa, 20% in CLL group and 33.3% in NHL group as regards lambda (Table 4).

Discussion

Modern hematopathology relies heavily on immunophenotyping both for distinguishing benign from malignant processes as well as for accurate subclassification. In addition, paraf-

fin section immunophenotyping allows us to make diagnoses on small biopsies that would have previously been considered suspicious for infiltration. In addition to the numerous commercially available antibodies, advances in heat-induced epitope retrieval allow one to obtain a detailed immunophenotype in routinely processed lymphomas that was only possible using flow cytometry or frozen section immunostaining.⁸

Although the use of antibody panels is standard in flow cytometry, the study of a full panel of paraffin-reactive antibodies in the workup

of B-cell lymphoid neoplasms is not so prevalent. A full immunophenotype and determination of monoclonality (immunoglobulin (Ig) light chain restriction) may be difficult using IHC because of the destruction of some of the antigenic epitopes by the fixation and decalcification process used for BMB specimens.⁹ In addition, some markers that are useful by flow cytometry are simply not routinely available for paraffin IHC.¹⁰

The aim of this study was to identify the diagnostic role of IHC in chronic B-cell neoplasms using a selected panel of monoclonal

Table 2. Comparing percent positivity of immunohistochemistry and flow cytometry in chronic lymphocytic leukemia and non Hodgkin lymphoma groups.

Marker		IHC (No of positive cases)	Flow cytometry (% positivity)	P	Sig.
CD20	CLL	9	76.9	0.814	NS
	NHL	21	49.1	0.01	S
CD5	CLL	11	53.1	0.237	NS
	NHL	11	6.3	0.02	S
CD23	CLL	5	67.2	0.118	NS
	NHL	3	6.1	0.049	S
Kappa	CLL	2	35	0.231	NS
	NHL	5	16.8	0.025	S
Lambda	CLL	1	2.4	0.251	NS
	NHL	7	5.9	0.006	HS

IHC, immunohistochemistry; CLL, chronic lymphocytic leukemia; NHL, non Hodgkin lymphoma; NS, Non-significant; S, Significant; HS, Highly-significant.

Table 3. Comparing percent positivity of immunohistochemistry and flow cytometry mean fluorescence intensity in chronic lymphocytic leukemia and non Hodgkin lymphoma groups.

Marker		IHC (No of positive cases)	Flow cytometry (MFI)	P	Sig.
CD20	CLL	9	1.77	0.002	HS
	NHL	21	20	0.002	HS
CD5	CLL	11	2.69	0.97	NS
	NHL	11	0	0.04	S
CD23	CLL	5	1.56	0.3	NS
	NHL	3	0	0.19	NS
Kappa	CLL	2	1.1	0.3	NS
	NHL	5	1.58	0.5	NS
Lambda	CLL	1	0	0.22	NS
	NHL	7	0	0.45	NS

IHC, immunohistochemistry; CLL, chronic lymphocytic leukemia; NHL, non Hodgkin lymphoma; NS, Non-significant; S, Significant; HS, Highly-significant.

Table 4. Sensitivity of immunohistochemistry markers in chronic lymphocytic leukemia and non Hodgkin lymphoma groups.

	CLL	NHL	Total
CD20	81.8%	100%	90%
CD5	100%	100%	100%
CD23	46%	66.7%	50%
Kappa	33.3%	50%	40%
Lambda	20%	33.3%	25%

CLL, chronic lymphocytic leukemia; NHL, non Hodgkin lymphoma.

antibodies and to compare this role to that of flow cytometry. Thirty five newly diagnosed patients having chronic B-LPDs were studied in the current study; they were classified into three groups (CLL, NHL and HCL).

Flow cytometry on bone marrow aspirate samples of CLL and infiltrated cases of NHL and IHC were performed on BMB samples using a panel of markers: CD20, CD5, CD23, Bcl2, Bcl6, kappa and lambda light chain.

Comparing IHC results with flow cytometry, the current study detected IHC sensitivity 90%, 100%, 50%, 40% and 25% for CD20, CD5, CD23, kappa and lambda respectively. The sensitivity of light chain by IHC was 33.3% in CLL and 50% in NHL as regards kappa chain, 20% in CLL and 33.3% in NHL as regards lambda chain.

Biesemier and his colleagues¹¹ compared IHC fresh frozen tissues to flow cytometry. They obtained lower concordant results as regards CD20 and CD5 being 86% and 80% respectively. The sensitivity of light chain restriction by IHC was 30% which is near to that in the present study.

In a study by El-Sayed and colleagues in 2008¹ done on Egyptians, they measured the overall concordance between IHC and flow cytometry without specifying each marker. The results of the study showed 88% concordance between flow cytometry and histopathology/IHC in the diagnosis of lymphoma. Similar results were obtained by Mandacova *et al.*¹² and Martinez *et al.*¹³ who found a concordance between flow cytometry and histopathology/IHC in 89% and 87.2% of B-lymphoma cases respectively.

In another study done on Egyptians by Asaad *et al.* in 2005,¹⁴ they studied CD23 and cyclin D1 immunostaining of lymph node biopsies in B-SLL/CLL and MCL cases. They found that CD23 was positive in 64% of B-CLL/SLL cases and 4% of MCL cases stained with a membranous pattern of staining.

In accordance, Sah and co-workers⁹ compared the results of flow cytometry, BMB and aspirates in 110 patients with B-cell lymphomas. In the CLL cases they showed a good correlation between the three parameters in over two thirds of samples and up to 88% when only flow cytometry and IHC were compared. There were very few discrepancies between flow cytometry and BMB and these were found mainly in cases with minimal residual disease (MRD). It seems, according to their study, that BMB/IHC and flow cytometry are the best methods to assess MRD in CLL.

Previous studies investigating the role of flow cytometry in detecting BM involvement by NHL has not provided evidence of much benefit beyond morphological examination alone in the biopsy. Fineberg *et al.*¹⁵ and Dunphy¹⁶ found a good correlation (85% and 81% respectively) between morphology on BMB and flow

cytometry, which can be explained in part by the inclusion of a large number of CLL cases.

A lower percentage of concordance between flow cytometry and BMB was estimated by Naughton *et al.*¹⁷ who reviewed 273 bone marrows from patients known to have NHL, where flow cytometry detected only 60% of positive BMB cases.

In our study, using a cut off $\geq 20\%$, bcl-2 protein was positive in 54.5% of CLL cases, 36.4% of NHL cases (80% of FL, 29% of MCL and 33% of Diffuse large B-cell lymphoma cases). Indeed, immunohistochemical studies have shown that, beside FL, a broad spectrum of lymphoid malignancies including CLL, plasma cell dyscrasia and Diffuse large B-cell lymphoma (DLBCL) also express the bcl-2 protein.¹⁸

Studying bcl-2 in lymphoma cases, Papakonstantinou *et al.* proved that the expression of bcl-2 protein is not restricted to B-cell lymphomas bearing the t(14; 18) translocation and they showed the complete absence of any correlation between bcl-2 gene rearrangements and bcl-2 expression in NHL.¹⁹

Despite using the same clone and the same cut off (20%) as in the current study, Chang *et al.*²⁰ found 100% positivity in CLL/SLL cases (29 cases). Also Papakonstantinou *et al.*¹⁹ detected 92% positivity in CLL cases.

Studying only Egyptian patients with de novo nodal DLBCL, Abd El-Hameed²¹ found that positivity for bcl-2 (using a lower cut off level > 10%) was detected in 60% cases.

In accordance to our results, Kondo *et al.*²² detected bcl-2 protein by IHC in 75% in FL and 44% in DLBCL. Similarly, Hadzi-Pecova *et al.*²³ found bcl-2 protein expression in 87% of the patients with FL and in 38% of cases with DLBCL.

Using a lower cut off > 5%, Llanos *et al.*²⁴ found 95% of FL and 61% of DLBCL cases expressing bcl-2 protein revealing a higher percent than that in this study. Also in a recent study by Chang *et al.*,²⁰ they found over 75% of bcl-2 protein positivity in NHL cases with a cut off 20%. Within their patients, the bcl-2 percent positivity was 93%, 56% and 100% among FL (59 cases), DLBCL (77 cases) and MCL (4 cases) respectively.

As for bcl-6, the current study showed positivity in 13.6% (3/22) of NHL cases and it was negative in all other groups. Two out of three cases were DLBCL and one was MCL.

Despite the small sample size of DLBCL in the current study, the percent of positive cases was in agreement with Lossos *et al.*²⁵ who showed expression in 63% of DLBCL cases. A slightly higher percent was obtained by Winter²⁶ (77%) and Colomo²⁷ (72%).

A lower percent in DLBCL was obtained by Chang²⁸ (51%) and Hans²⁹ (56%). According to

Winter *et al.*,²⁶ such differences may represent the underlying patient population as well as technical factors related to staining, interpretation, and scoring of positive results.

Authors were contradicting in establishing a cut off value ranging from 10-30%.^{25,27,30-33} These differences may partly be explained by the differences in the staining techniques, for instance a study using the EnVision method and a low cut off of 10%, as much as 97% of cases were found positive for bcl-6.³⁴

The aberrant expression of bcl-6 in MCL found in the current study was also experienced by some authors. Only one of 20 MCL cases studied by Chuang *et al.*³⁵ expressed bcl-6. Similarly, Gualco *et al.*³⁶ found bcl-6 expression in 12% of the MCL cases.

We concluded that IHC can be a reliable alternative choice for IPT especially in NHL cases. Both IHC and flow cytometry are effective in diagnosing CLL; however, IHC might be slightly more sensitive than flow cytometry in detecting BM infiltration in NHL and HCL.

References

1. El-Sayed AM, El-Borai MH, Bahnassy AA, El-Gerzawi SM. Flow cytometric immunophenotyping (FCI) of lymphoma: correlation with histopathology and immunohistochemistry. *Diagn Pathol* 2008;3:43.
2. Matutes E, Morilla R, Catovsky D. Immunophenotyping. Dacie and Lewis Practical Haematology (Tenth Edition); 2006. pp 335-355
3. Gudgin EJ, Erber WN. Immuno-phenotyping of lymphoproliferative disorders: state of the art. *Pathology* 2005;37:457-78.
4. Ioachim HL, Medeiros LJ. Flow cytometry and Immunohistochemistry. In: Ioachim's lymph node pathology. Philadelphia: Lippincott Williams and Wilkins 4th edition; 2008. pp 38-57.
5. Dunphy CH. Applications of flow cytometry and immunohistochemistry to diagnostic hematopathology. *Arch Pathol Lab Med* 2004;128:1004-22.
6. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. *Leukemia* 1994;10:1640-5.
7. Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). *Am J Clin Pathol* 1997;108:378-82.
8. Hsi ED, Yegappan S. Lymphoma immunophenotyping: a new era in paraffin-section immunohistochemistry. *Adv Anat Pathol* 2001;8:218-39.
9. Sah SP, Matutes E, Wotherspoon AC, et al.

- A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders. *J Clin Pathol* 2003;56:129-32.
10. Higgins RA, Blankenship JE, Kinney MC. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. *Arch Pathol Lab Med* 2008;132:441-61.
 11. Biesemier KW, Dent GA, Pryzwansky KB, Folds JD. A comparative study of frozen-section immunoperoxidase and flow cytometry for immunophenotypic analysis of lymph node biopsies. *Clin Diagn Lab Immunol* 1994;1:299-303.
 12. Mandakova P, Campr V, Kodet R. Correlation of results of flow cytometry and morphologic findings in the diagnosis of malignant B-cell lymphoma. *Cas Lek Cesk* 2003;142:651-5.
 13. Martinez A, Aymerich M, Castillo M, et al. Routine use of immunophenotype by flow cytometry in tissues with suspected hematological malignancies. *Cytometry B Clin Cytom* 2003;56:8-15.
 14. Asaad NY, Abd El-Wahed MM, Dawoud MM. Diagnosis and Prognosis of B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (B-CLL/SLL) and Mantle Cell Lymphoma (MCL). *J Egypt Nat Cancer Inst* 2055;17:279-90.
 15. Fineberg S, Marsh E, Alfonso F, et al. Immunophenotypic evaluation of bone marrow in non-Hodgkin's lymphoma. *Hum Pathol* 1993;24:636-42.
 16. Dunphy CH. Combining morphology and flow cytometric immunophenotyping to evaluate bone marrow specimens for B-cells malign neoplasms. *Am J Clin Pathol* 1998;109:625-30.
 17. Naughton MJ, Hess JL, Zutter MM, Bartlett NL. Bone marrow staging in patients with non-Hodgkin's lymphoma. Is flow cytometry a useful test? *Cancer* 1998;82:1154-9.
 18. Pezzella F, Tse AG, Cordell JL, et al. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. *Am J Pathol* 1990;137:225-32.
 19. Papakonstantinou G, Verbeke C, Hastka J, et al. Bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements. *Br J Haematol* 2001;113:383-90.
 20. Chang CM, Schroeder JC, Huang WY, et al. Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations: utility of fluorescence in situ hybridization (FISH) in a case-control study. *Leuk Res* 2010;34:190-5.
 21. Abd El-Hameed A. De novo nodal diffuse large B-cell lymphoma: identification of biologic prognostic factors. *J Egypt Nat Cancer Inst* 2005;1:20-8.
 22. Kondo E, Yoshino T, Yamadori I, et al. Expression of Bcl-2 Protein and Fas Antigen in Non-Hodgkin's Lymphomas. *Am J Clin Pathol* 1994;145:330-7.
 23. Hadzi-Pecova L, Petrussevska G, Stojanovic A. Non-Hodgkin's lymphomas: immunologic prognostic studies. *Prilozi* 2007;28:39-55.
 24. Llanos M, Alvarez-Argüelles H, Alemán R, et al. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. *Med Oncol* 2001;18:15-22.
 25. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. *Blood* 2001;98:945-51.
 26. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. *Blood* 2006;107:4207-13.
 27. Colomo L, López-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. *Blood* 2003;101:78-84.
 28. Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. *Am J Surg Pathol* 2004;28:464-70.
 29. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood* 2004;103:275-82.
 30. Barrans SL, O'Connor SJM, Evans PAS, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. *Br J Haematol* 2002;117:322-32.
 31. Berglund M, Thunberg U, Amini RM, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. *Mod Pathol* 2005;18:1113-20.
 32. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. *Am J Surg Pathol* 2000;24:846-52.
 33. De Leval L, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. *Histopathology* 2003;43:509-28.
 34. Linderth J, Jerkeman M, Cavallin-Ståhl E, et al. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. *Clin Cancer Res* 2003;9:722-8.
 35. Chuang SS, Huang WT, Hsieh PP, et al. Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. *Pathol Int* 2006;56:440-8.
 36. Gualco G, Weiss LM, Harrington WJ Jr, Bacchi CE. BCL6, MUM1, and CD10 expression in mantle cell lymphoma. *Appl Immunohistochem Mol Morphol* 2010;18:103-8.